235 related articles for article (PubMed ID: 28029307)
1. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.
Weldon CB; Madenci AL; Boikos SA; Janeway KA; George S; von Mehren M; Pappo AS; Schiffman JD; Wright J; Trent JC; Pacak K; Stratakis CA; Helman LJ; La Quaglia MP
J Clin Oncol; 2017 Feb; 35(5):523-528. PubMed ID: 28029307
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
4. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
[TBL] [Abstract][Full Text] [Related]
5. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
6. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
[TBL] [Abstract][Full Text] [Related]
7. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
Nannini M; Biasco G; Astolfi A; Pantaleo MA
J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252
[TBL] [Abstract][Full Text] [Related]
8. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.
Rege TA; Wagner AJ; Corless CL; Heinrich MC; Hornick JL
Am J Surg Pathol; 2011 Apr; 35(4):495-504. PubMed ID: 21358303
[TBL] [Abstract][Full Text] [Related]
9. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
11. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Joensuu H; Rutkowski P; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Braconi C; Bordoni A; Magnusson MK; Sufliarsky J; Federico M; Jonasson JG; Hostein I; Bringuier PP; Emile JF
J Clin Oncol; 2015 Feb; 33(6):634-42. PubMed ID: 25605837
[TBL] [Abstract][Full Text] [Related]
12. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.
Hou YY; Grabellus F; Weber F; Zhou Y; Tan YS; Li J; Shen KT; Qin J; Sun YH; Qin XY; Bockhorn M; Gerken G; Broelsch CE; Frilling A
J Gastrointest Surg; 2009 Sep; 13(9):1583-92. PubMed ID: 19291337
[TBL] [Abstract][Full Text] [Related]
13. Divergent gastrointestinal stromal tumors in syndromic settings.
Ricci R; Martini M; Cenci T; Riccioni ME; Maria G; Cassano A; Larocca LM
Cancer Genet; 2016; 209(7-8):354-8. PubMed ID: 27318444
[TBL] [Abstract][Full Text] [Related]
14. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
16. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
Singer S; Rubin BP; Lux ML; Chen CJ; Demetri GD; Fletcher CD; Fletcher JA
J Clin Oncol; 2002 Sep; 20(18):3898-905. PubMed ID: 12228211
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
19. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
20. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.
Rizzo FM; Palmirotta R; Marzullo A; Resta N; Cives M; Tucci M; Silvestris F
BMC Cancer; 2016 Feb; 16():87. PubMed ID: 26867653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
